Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEND-1 with Gemcitabine and Nab-Paclitaxel in Metastatic Pancreatic Cancer
NCT03517176Phase 1Completed
- Sponsor
- Lisata Therapeutics
- Start
- Jul 2018
- Primary completion
- Jun 2020
- Modality
- Cyclic Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of certepetide in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by Lisata Therapeutics. Primary endpoints: Safe doses of CEND-1 and Optimal Biological Dose. Started Jul 2018; status: completed.
02
Drugs
certepetide
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03517176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03517176.